AR and pachyonychia congenita: Previous clinical studies on AR-V7 testing focused on retrospective or prospective cohort analyses of associated AR-V7 expression distinguishing subgroups with different clinical outcomes with hormonal treatment in men with metastatic PC.37–40 However, the highest level of assessment of clinical worth in improving patient outcomes (clinical utility) remains lacking.